Stay updated on Subcutaneous Durvalumab in Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the Subcutaneous Durvalumab in Lung Cancer Clinical Trial page.

Latest updates to the Subcutaneous Durvalumab in Lung Cancer Clinical Trial page
- Check3 days agoChange DetectedThe page’s displayed software/version identifier was incremented from “v3.5.2” to “v3.5.3,” indicating a minor site update without altering the trial record information.SummaryDifference0.2%

- Check10 days agoChange DetectedThe page history shows a new site revision (v3.5.2) replacing the previous revision (v3.5.0).SummaryDifference0.1%

- Check17 days agoNo Change Detected
- Check39 days agoChange DetectedFooter revision updated from v3.4.3 to v3.5.0; no changes to study data or page content.SummaryDifference0.1%

- Check46 days agoChange DetectedAdded Revision: v3.4.3 to the history and removed Revision: v3.4.2.SummaryDifference0.1%

- Check75 days agoChange DetectedRevision: v3.4.2 was added and the v3.4.1 notice about government funding was removed; these are administrative updates that do not affect core study data. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.6%

- Check82 days agoChange DetectedAdded a site-wide notice about a lapse in government funding affecting updates and changed the page revision to v3.4.1; the previous v3.4.0 entry was removed.SummaryDifference0.6%

Stay in the know with updates to Subcutaneous Durvalumab in Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Subcutaneous Durvalumab in Lung Cancer Clinical Trial page.